Progress in targeted therapy for breast cancer

Ju, Jie; Zhu, Anjie; Yuan, Peng

doi:10.1016/j.cdtm.2018.04.002

Cited by 41 publications

(47 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common cause of hereditary breast cancer is an inherited mutation in the BRCA1 or BRCA2 gene, which are tumor suppressor genes involved in such essential functions as DNA repair [87,88]. There are various biological processes and genetic mutations that lead to the appearance of breast cancer and sensitivity to various drugs, such as hormone receptor, human epidermal growth factor receptor 2 (HER2), EGF, vascular endothelial growth factor (VEGF), mechanistic target of rapamycin (mTOR), and cyclin-dependent kinase 4/6 (CDK4/6) [89]. Women, compared to men, present a 100-fold increased risk of having breast cancer; furthermore, aging and heredity also contribute as predisposing factors to the disease [88].…”

Section: Nanotheranostics In Diagnosis and Treatment Of Cancermentioning

confidence: 99%

Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems

et al. 2019

View full text Add to dashboard Cite

Theranostics has emerged in recent years to provide an efficient and safer alternative in cancer management. This review presents an updated description of nanotheranostic formulations under development for skin cancer (including melanoma), head and neck, thyroid, breast, gynecologic, prostate, and colon cancers, brain-related cancer, and hepatocellular carcinoma. With this focus, we appraised the clinical advantages and drawbacks of metallic, polymeric, and lipid-based nanosystems, such as low invasiveness, low toxicity to the surrounding healthy tissues, high precision, deeper tissue penetration, and dosage adjustment in a real-time setting. Particularly recognizing the increased complexity and multimodality in this area, multifunctional hybrid nanoparticles, comprising different nanomaterials and functionalized with targeting moieties and/or anticancer drugs, present the best characteristics for theranostics. Several examples, focusing on their design, composition, imaging and treatment modalities, and in vitro and in vivo characterization, are detailed herein. Briefly, all studies followed a common trend in the design of these theranostics modalities, such as the use of materials and/or drugs that share both inherent imaging (e.g., contrast agents) and therapeutic properties (e.g., heating or production reactive oxygen species). This rationale allows one to apparently overcome the heterogeneity, complexity, and harsh conditions of tumor microenvironments, leading to the development of successful targeted therapies.

show abstract

Section: Nanotheranostics In Diagnosis and Treatment Of Cancermentioning

confidence: 99%

Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, only 5% of molecules that show anticancer activity in preclinical studies are approved upon demonstration of sufficient efficacy in phase III clinical trials [90]. This trend is extremely prevalent especially for vascular endothelial growth factor (VEGF) inhibitors (e.g., Bevacizumab), which are also used for BC treatment [91]. As reported for AD [56][57][58][59][60][61], incorrect identification of drug targets, improper proposed mechanism of action, drug toxicity, drug resistance, and weak genetic evidence are among the possible failure reasons [22].…”

Section: Breast Cancermentioning

confidence: 99%

Alzheimer’s Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research

Herrmann

Bernasconi

McCarthy

et al. 2020

Animals

View full text Add to dashboard Cite

Dementia and cancer are becoming increasingly prevalent in Western countries. In the last two decades, research focused on Alzheimer’s disease (AD) and cancer, in particular, breast cancer (BC) and prostate cancer (PC), has been substantially funded both in Europe and worldwide. While scientific research outcomes have contributed to increase our understanding of the disease etiopathology, still the prevalence of these chronic degenerative conditions remains very high across the globe. By definition, no model is perfect. In particular, animal models of AD, BC, and PC have been and still are traditionally used in basic/fundamental, translational, and preclinical research to study human disease mechanisms, identify new therapeutic targets, and develop new drugs. However, animals do not adequately model some essential features of human disease; therefore, they are often unable to pave the way to the development of drugs effective in human patients. The rise of new technological tools and models in life science, and the increasing need for multidisciplinary approaches have encouraged many interdisciplinary research initiatives. With considerable funds being invested in biomedical research, it is becoming pivotal to define and apply indicators to monitor the contribution to innovation and impact of funded research. Here, we discuss some of the issues underlying translational failure in AD, BC, and PC research, and describe how indicators could be applied to retrospectively measure outputs and impact of funded biomedical research.

show abstract

“…According to the progression in breast cancer pathogenesis, it has been found that hormonebased signaling pathways as well as their receptors are crucial in breast cancer and breast cancer-targeted hormone therapy plays an important role in clinical treatment [20]. The main receptors regarding in breast cancer are HER2, IFNɣR, TNFαR and PR.…”

Section: Diagrammentioning

confidence: 99%

The Antiangiogenic Effects of Tamoxifen might be Attributed to Receptor Binding Capacity of its Solvent Dimethylsulfoxide in Breast Cancer: A Molecular Docking Study

Koçak

Taşkın

Şimşek

2019

JPRI

View full text Add to dashboard Cite

Aim: Tamoxifen, a Dimethyl sulfoxide (DMSO)-soluble chemotherapeutic, is widely used in the treatment of breast cancer. Tamoxifen has an anti-angiogenic effect especially on breast tumor cells by blocking VEGF(Vascular Endothelial Growth Factor) production. On the other hand, according to our previously studies, we demonstrated that DMSO could mimics the cytotoxic effects of Thalidomide in 4T1 mouse breast cancer cells and is related with the anti-angiogenic response of HeLa cells. At this point of view, the aim of this study was to determine the possible binding effects of DMSO on certain cell surface receptors. Methods: The in silico studies were implemented using the Docking Server. X-ray structures of receptor proteins’ PDB files were obtained from Protein Data Bank [Human Progesteron Receptor (PDB ID: 1A28, Human Tumor Necrosis Factor Receptor-1 (PDB ID: 1EXT), Human Interferon Gamma Receptor-1 (PDB ID: 1FG9), Human Epidermal Growth Factor Receptor (PDB ID: 1IVO)]. Docking simulations were performed using the Lamarckian genetic algorithm (LGA) and the Solis & Wets local search method. Results: According to the molecular docking results of this study, DMSO, the general solvent of Tamoxifen, has a 90% binding capacity to the Interferon Gamma (IFNɣ) receptor and 100% to Tumor Necrosis Factor alfa (TNFα) receptor, respectively. Conclusion: These receptors have significant effects on the proliferation and angiogenesis of cancer cells which leads to the metastasis of breast cancer. In conclusion, the antiangiogenic effects of Tamoxifen might be reduced due to its solvent DMSO's angiogenic effects.

show abstract

Progress in targeted therapy for breast cancer

Cited by 41 publications

References 53 publications

Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems

Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems

Alzheimer’s Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research

The Antiangiogenic Effects of Tamoxifen might be Attributed to Receptor Binding Capacity of its Solvent Dimethylsulfoxide in Breast Cancer: A Molecular Docking Study

Contact Info

Product

Resources

About